Select Issuer Clients

Select Issuer Clients

Issuer Client Profile

DelMar Pharmaceuticals, Inc. (DMPI)

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer. View Website

Stock Info

DelMar Pharmaceuticals, Inc. NASDAQ: DMPI
Volume
Day Range
52 wk Range
Market Cap

Stock Quotes are delayed at least 15 minutes.

Issuer Client News Feed

For Investors

Want to take part in the next big idea?

Join Our Network

For Entrepreneurs

Want to explore how we add value?

Submit Your Business Plan